鼠神经生长因子治疗中重度颅脑损伤的有效性和安全性

doi:10.3877/cma.j.issn.2095-9141.2016.03.002

目的

观察注射用鼠神经生长因子治疗中重度颅脑损伤的临床疗效及安全性。

方法

选取自2012年2月至2015年12月陆军总医院附属八一脑科医院一病区接诊的60例中重度颅脑损伤患者作为研究对象，按随机数字表分为观察组30例和对照组30例，对照组进行常规方法治疗，观察组在对照组的基础上再肌内注射鼠神经生长因子，30 μg/次，每日1次，治疗时间为3周，所有患者随访3个月。治疗前、治疗3周、随访3个月进行格拉斯哥昏迷（GCS）评分、格拉斯哥结果（GOS）评分、日常生活能力（ADL）评分、蒙特利尔认知评估量表（MoCA）评分，记录ICU住院天数，统计死亡率，评判两组临床疗效。

结果

观察组和对照组治疗3周、随访3个月的GCS、ADL、MoCA评分较治疗前明显升高，F=3.664、11.827、9.667和3.028、9.808、8.623，P<0.05或P<0.01，且观察组治疗3周GCS、ADL、MoCA、GOS评分高于对照组，且差异均有统计学意义（t=3.526、3.665、3.862、3.448，P<0.05），随访3个月ADL评分高于对照组，且差异有统计学意义（t=3.472，P<0.05）。观察组的临床总有效率为86.7%，高于对照组的60.0%，且差异有统计学意义（χ²=6.393，P<0.05），两组患者ICU停留时间差异无统计学意义（t=0.339，P>0.05）。

结论

注射用鼠神经生长因子治疗中重度颅脑损伤疗效确切且安全性良好，能够快速促进神经功能缺损恢复，且对合并颅神经损伤也有积极影响，值得临床推广使用。

关键词: 颅脑损伤, 颅神经损伤, 鼠神经生长因子, 治疗结果, 安全性

Objective

To observe the clinical study of the safety and efficacy of mouse nerve growth factor for injection in treatment of moderate and severe head trauma.

Methods

Totally 60 patients with moderate and severe head trauma in The Affiliated Bayi Brain Hospital, PLA Army General Hospital from February 2012 to December 2015 were included as research subjects. All patients were randomly divided into 30 cases of the observation group and 30 cases of the control group. The control group were received conventional treatment. The observation group were additionally received 30 μg mouse nerve growth factor for injection, once a day, for 3 week, all patients were followed up for 3 months, the GCS, GOS, ADL, MoCA score were recorded before treatment, after 3 weeks treatment and 3 months follow-up, the ICU length of stay, mortality rate were recorded, total clinical efficiency were evaluated.

Results

the GCS, ADL, MoCA score of the observation group and the control group after 3 weeks treatment and follow-up three months were significantly higher than before treatment, F=3.664, 11.827, 9.667 and 3.028, 9.808, 8.623, P<0.05 or P<0.01, and the GCS, ADL, MoCA, GOS score of the observation group after 3 weeks were significantly higher than the control group, t=3.526, 3.665, 3.862, 3.448, all P<0.05, ADL score 3-month follow-up were significantly higher than the control group, t=3.472, P<0.05. the clinical effective rate of the observation group were 86.67%, and the control group were 60%,the difference was significant, χ²=6.393, P<0.05, the ICU stay was not significantly different between both group, t=0.339, P>0.05.

Conclusion

The mouse nerve growth factor for inject have exact efficacy and good security, can quickly promote the recovery of neurological deficit, and also has a positive effect on the consolidated cranial nerve injury, worthy of clinical use.

Key words: Head trauma, Cranial nerve injury, Mouse nerve growth factor, Treatment outcome, Safety

表1 两组患者治疗前后各量表评分结果（分，±s）

组别	n	?	GCS	ADL	MoCA	GOS
观察组	30	治疗前	8.75±2.55	4.85±13.84	2.05±6.46	-
?	?	治疗3周	13.55±3.43^a	68.32±35.64^b	24.43±11.55^c	4.33±0.95^e
?	?	随访3个月	14.35±2.26	93.58±30.66^d	25.58±9.18	4.67±0.86
?	?	组内F值或t值	3.664	11.827	9.667	1.228
?	?	组内P值	<0.05	<0.01	<0.01	>0.05
对照组	30	治疗前	8.69±2.58	4.78±15.92	2.00±6.68	-
?	?	治疗3周	11.96±3.72	54.55±40.21	17.50±12.97	3.68±1.04
?	?	随访3个月	13.91±2.37	79.09±35.04	24.45±10.09	4.18±1.10
?	?	组内F值或t值	3.028	9.808	8.623	3.007
?	?	组内P值	<0.05	<0.01	<0.01	<0.05

表1 两组患者治疗前后各量表评分结果（分，±s）

组别	n	?	GCS	ADL	MoCA	GOS
观察组	30	治疗前	8.75±2.55	4.85±13.84	2.05±6.46	-
?	?	治疗3周	13.55±3.43^a	68.32±35.64^b	24.43±11.55^c	4.33±0.95^e
?	?	随访3个月	14.35±2.26	93.58±30.66^d	25.58±9.18	4.67±0.86
?	?	组内F值或t值	3.664	11.827	9.667	1.228
?	?	组内P值	<0.05	<0.01	<0.01	>0.05
对照组	30	治疗前	8.69±2.58	4.78±15.92	2.00±6.68	-
?	?	治疗3周	11.96±3.72	54.55±40.21	17.50±12.97	3.68±1.04
?	?	随访3个月	13.91±2.37	79.09±35.04	24.45±10.09	4.18±1.10
?	?	组内F值或t值	3.028	9.808	8.623	3.007
?	?	组内P值	<0.05	<0.01	<0.01	<0.05

表2 两组患者临床疗效比较

组别	例数	痊愈[例(%)]	好转[例(%)]	好转[例(%)]	总有效率(%)	ICU停留时间（d，±s）
观察组	30	11(36.67)	15(50.00)	4(13.33)	86.7	4.22±2.08
对照组	30	5(16.67)	13(43.33)	12(40.00)	60.0	4.57±2.13
检验值	?	-	-	-	χ²=6.393	t=0.339
P值	?	-	-	-	<0.05	>0.05

表2 两组患者临床疗效比较

组别	例数	痊愈[例(%)]	好转[例(%)]	好转[例(%)]	总有效率(%)	ICU停留时间（d，±s）
观察组	30	11(36.67)	15(50.00)	4(13.33)	86.7	4.22±2.08
对照组	30	5(16.67)	13(43.33)	12(40.00)	60.0	4.57±2.13
检验值	?	-	-	-	χ²=6.393	t=0.339
P值	?	-	-	-	<0.05	>0.05

[1]	Hansen-Algenstaedt N,Algenstaedt P,Schaefer C, et al. Neural driven angiogenesis by overexpression of nerve growth factor[J]. Histochem Cell Biol, 2006, 125(6): 637-649.
[2]	Jin Y,Ziemba KS,Smith GM. Axon growth across a lesion site along a preformed guidance pathway in the brain[J]. Exp Neurol, 2008, 210(2): 521-530.
[3]	Chiaretti A,Antonelli A,Mastrangelo A, et al. Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury[J]. J Neurotrauma, 2008, 25(3): 225-234.
[4]	韩宗利,王诚,刘胜,等.神经生长因子在颅脑损伤救治中的应用[J].华中医学杂志, 2009, 33(3): 134-136.
[5]	齐辉,郑思阳,吴广源,等.神经生长因子治疗重型颅脑损伤的临床观察[J].临床和实验医学杂志, 2009, 8(7): 125-128.
[6]	刘明铎.实用颅脑损伤学[M].北京:人民军医出版社, 1995: 331.
[7]	Palzur E,Vlodavsky E,Mulla H, et al. Hyperbaric oxygen therapy for reduction of secondary brain damage in head injury animal model of brain contusion[J]. J Neurotrauma, 2004, 21(1): 4l-48.
[8]	Chiaretti A,Antonelli A,Genovese O, et al. Intraventricular nerve growth factor infusion improves cerebral blood flow and stimulates doublecortin expression in two infants with hypoxic-ischemic brain injury[J]. Neurol Res, 2008, 30(3): 223-228.
[9]	Nudo RJ. Mechanisms for recovery of motor function following cortical damage[J]. Curr Opin Neurobiol, 2006, 16(6): 638-644.
[10]	Chiaretti A,Barone G,Riccardi R, et al. NGF, DCX, and NSE upregulation correlates with severity and outcome of head trauma in children[J]. Neurology, 2009, 72(7): 609-616.
[11]	Yang JP,Liu XF,Liu HJ, et al. Extracellular signa-regulated kinase involved in NGF/VEGF-induced neuroprotective effect[J]. Neurosci Lett, 2008, 434(2): 212-217.
[12]	王英超,孙红梅,董振香,等.注射用鼠神经生长因子[J].中国新药杂志, 2007, 16(18): 1538-1539.

[1]	许正文, 李振, 侯振扬, 苏长征, 朱彪. 富血小板血浆联合植骨治疗早期非创伤性股骨头坏死[J]. 中华关节外科杂志(电子版), 2023, 17(06): 773-779.
[2]	王宏宇. 固定与活动平台假体在全膝关节置换术中的应用价值[J]. 中华关节外科杂志(电子版), 2023, 17(06): 871-876.
[3]	高玲, 于哲, 范然, 臧银善. 外周血细胞计数比值评估类风湿关节炎疗效的价值[J]. 中华关节外科杂志(电子版), 2023, 17(05): 642-647.
[4]	王泽勇, 覃健. 白细胞含量对富血小板血浆治疗运动系统损伤的影响[J]. 中华关节外科杂志(电子版), 2023, 17(05): 684-688.
[5]	陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[6]	张海涛, 康婵娟, 翟静洁. 胰管支架置入治疗急性胆源性胰腺炎效果观察[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 654-657.
[7]	熊风, 林辉煌, 陈晓波. 铥激光在泌尿外科中的临床应用及研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 533-536.
[8]	彭永辉, 张文杰, 李炳根, 聂向阳, 吴凯, 杨六成. 单孔双针疝囊高位结扎术在儿童巨大腹股沟疝的临床应用[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(05): 566-569.
[9]	刘骏, 朱霁, 殷骏. 右美托咪定对腹股沟疝手术麻醉效果及安全性的影响[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(05): 570-573.
[10]	王峰杰, 王礼光, 廖珊, 刘颖, 符荣党, 陈焕伟. 腹腔镜右半肝切除术治疗肝癌的安全性与疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 517-522.
[11]	李飞翔, 段虎斌, 李晋虎, 吴昊, 王永红, 范益民. 急性颅脑损伤继发下肢静脉血栓的相关危险因素分析及预测模型构建[J]. 中华神经创伤外科电子杂志, 2023, 09(05): 277-282.
[12]	潘立, 谢理政, 程宏伟, 茆翔. 创伤性颅脑损伤后垂体功能减退[J]. 中华神经创伤外科电子杂志, 2023, 09(05): 308-312.
[13]	梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
[14]	朴成林, 蓝炘, 司振铎, 冯健, 安峰铎, 李强, 谈明坤, 赵娜, 冷建军. 局部晚期右半结肠癌行结肠癌根治联合胰十二指肠切除术疗效分析：附5例报告[J]. 中华临床医师杂志(电子版), 2023, 17(06): 666-670.
[15]	曹文玺, 陈箫, 竺来法, 周永平. 尼妥珠单抗联合白蛋白结合型紫杉醇治疗胰腺癌的有效性及安全性分析[J]. 中华临床医师杂志(电子版), 2023, 17(04): 409-413.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

The clinical study of the safety and efficacy of mouse nerve growth factor in treatment of moderate and severe head trauma

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

The clinical study of the safety and efficacy of mouse nerve growth factor in treatment of moderate and severe head trauma